These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30670037)

  • 1. First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda.
    Poon AFY; Ndashimye E; Avino M; Gibson R; Kityo C; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ;
    AIDS Res Ther; 2019 Jan; 16(1):3. PubMed ID: 30670037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
    Ayitewala A; Kyeyune F; Ainembabazi P; Nabulime E; Kato CD; Nankya I
    AIDS Res Ther; 2020 Jan; 17(1):2. PubMed ID: 32005262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
    Lam EP; Moore CL; Gotuzzo E; Nwizu C; Kamarulzaman A; Chetchotisakd P; van Wyk J; Teppler H; Kumarasamy N; Molina JM; Emery S; Cooper DA; Boyd MA
    AIDS Res Hum Retroviruses; 2016 Sep; 32(9):841-50. PubMed ID: 27346600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New subtypes and genetic recombination in HIV type 1-infecting patients with highly active antiretroviral therapy in Peru (2008-2010).
    Yabar CA; Acuña M; Gazzo C; Salinas G; Cárdenas F; Valverde A; Romero S
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1712-22. PubMed ID: 22559065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches.
    Lee GQ; Bangsberg DR; Mo T; Lachowski C; Brumme CJ; Zhang W; Lima VD; Boum Y; Mwebesa BB; Muzoora C; Andia I; Mbalibulha Y; Kembabazi A; Carroll R; Siedner MJ; Haberer JE; Mocello AR; Kigozi SH; Hunt PW; Martin JN; Harrigan PR
    AIDS; 2017 Nov; 31(17):2345-2354. PubMed ID: 28832407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa.
    Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S
    J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.
    Ndashimye E; Avino M; Kyeyune F; Nankya I; Gibson RM; Nabulime E; Poon AFY; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
    AIDS Res Hum Retroviruses; 2018 May; 34(5):404-414. PubMed ID: 29353487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
    Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
    AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
    Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
    Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.
    Bachmann N; von Braun A; Labhardt ND; Kadelka C; Günthard HF; Sekaggya-Wiltshire C; Castelnuovo B; Kambugu A; Lejone TI; Böni J; Yerly S; Perreau M; Klimkait T; Kouyos RD; Fehr J;
    J Antimicrob Chemother; 2019 Feb; 74(2):468-472. PubMed ID: 30476115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba.
    Kourí V; Alemán Y; Pérez L; Pérez J; Fonseca C; Correa C; Aragonés C; Campos J; Álvarez D; Schrooten Y; Dekeersmaeker N; Imbrechts S; Beheydt G; Vinken L; Pérez D; Álvarez A; Soto Y; Vandamme AM; Van Laethem K
    J Clin Virol; 2012 Dec; 55(4):348-55. PubMed ID: 22981617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
    Sacktor N; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Grabowski MK; Kisakye A; Batte J; Mayanja R; Anok A; Gray RH; Wawer MJ
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):216-223. PubMed ID: 30865184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
    Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
    Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
    Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of HIV-1 Subtypes and Antiretroviral Drug Resistance Mutations in Nepal.
    Bhusal N; Sutthent R; Horthongkham N; Athipanyasilp N; Kantakamalakul W
    Curr HIV Res; 2016; 14(6):517-524. PubMed ID: 27697032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda.
    Brennan CA; Lund JK; Golden A; Yamaguchi J; Vallari AS; Phillips JF; Kataaha PK; Jackson JB; Devare SG
    AIDS; 1997 Dec; 11(15):1823-32. PubMed ID: 9412700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    Villabona-Arenas CJ; Vidal N; Guichet E; Serrano L; Delaporte E; Gascuel O; Peeters M
    AIDS; 2016 Nov; 30(17):2577-2589. PubMed ID: 27603287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.